Страница 1 от 60 резултата
TECHNICAL FIELD
This invention pertains to compounds and methods that are useful in blocking intracellular signal transduction factors, and in preventing or treating inflammation, autoimmune diseases, and cancer.
BACKGROUND ART
Thiazole and thiophene derivatives have been used as therapeutic agents
FIELD OF THE INVENTION
The present invention is directed to compounds, methods, and compositions for the treatment of cancer, neurological disorders, and fibrotic disorders.
BACKGROUND
Every year, cancer claims the lives of more than half a million Americans. Cancer is the second leading cause of
FIELD OF THE INVENTION
The present invention is directed to compounds, methods, and compositions for the treatment of cancer, neurological disorders, and fibrotic disorders.
BACKGROUND
Every year, cancer claims the lives of more than half a million Americans. Cancer is the second leading cause of
FIELD OF THE INVENTION
The present invention is directed to compounds, methods, and compositions for the treatment of cancer, neurological disorders, and fibrotic disorders.
BACKGROUND
Every year, cancer claims the lives of more than half a million Americans. Cancer is the second leading cause of
FIELD OF THE INVENTION
The present invention is directed to compounds, methods, and compositions for the treatment of cancer, neurological disorders, and fibrotic disorders.
BACKGROUND
Every year, cancer claims the lives of more than half a million Americans. Cancer is the second leading cause of
FIELD OF THE INVENTION
The present invention relates to compounds that inhibit certain integrins, particularly to compounds that inhibit .alpha..sub.v integrins.
BACKGROUND OF THE INVENTION
Integrins are a major family of adhesion receptors. They are produced by most cell types and are a means by
BACKGROUND OF THE INVENTION
The present invention is directed to 2,3-substituted thiophenes. In particular, the present invention is directed to (2-carboxamido)(3-amino)thiophenes that are inhibitors of c-Kit proto-oncogene (also known as Kit, CD-117, stem cell factor receptor, mast cell growth
TECHNICAL FIELD
The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory
TECHNICAL FIELD
The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory
TECHNICAL FIELD
The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory
TECHNICAL FIELD
The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory
FIELD OF THE INVENTION
The present invention relates to a novel class of hydroxamic acid derivatives having a benzothiophene or thiophene backbone. The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit histone deacetylase and are suitable for use
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to thiophene derivatives active as kinase inhibitors and, more in particular, it relates to 3-aminocarbonyl-2-carboxamido-thiophene derivatives, to a process for their preparation, to pharmaceutical compositions
BACKGROUND OF THE INVENTION
6-Hydroxy-3-(4-[2-(piperidin-1-yl)ethoxyl]phenoxy)-2-(4-methoxyphenyl)benzo [b]thiophene hydrochloride (arzoxifene) was first described generically in U.S. Pat. No. 5,510,357 and was specifically disclosed in U.S. Pat. No. 5,723,474 ('474) and European Patent Application
BACKGROUND OF THE INVENTION
6-Hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[ b]thiophene hydrochloride (arzoxifene) was first described generically in U.S. Pat. No. 5,510,357 and was specifically disclosed in U.S. Pat. No. 5,723,474 ('474) and European Patent Application